Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Co.'s pipeline consists of six product candidates, two of which it is pursuing as product candidates for development, FT-4202 for the treatment of sickle cell disease, and other hemoglobinopathies, and FT-7051 for the treatment of metastatic castration-resistant prostate cancer, or mCRPC. FT-7051 and FT-6876 (a research compound) are inhibitors of the bromodomain of CBP/p300 that Co. has developed with the goal of generating treatments for mCRPC. The FMTX stock yearly return is shown above.
The yearly return on the FMTX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the FMTX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|